Last reviewed · How we verify
SGLT2 inhibitor and DPP-4 inhibitor
SGLT2 inhibitor and DPP-4 inhibitor is a SGLT2 inhibitor and DPP-4 inhibitor combination Small molecule drug developed by LMC Diabetes & Endocrinology Ltd.. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: Ertugliflozin and Sitagliptin.
This combination drug lowers blood glucose by blocking kidney glucose reabsorption (SGLT2 inhibitor) and slowing incretin hormone breakdown (DPP-4 inhibitor).
This combination drug lowers blood glucose by blocking kidney glucose reabsorption (SGLT2 inhibitor) and slowing incretin hormone breakdown (DPP-4 inhibitor). Used for Type 2 diabetes mellitus.
At a glance
| Generic name | SGLT2 inhibitor and DPP-4 inhibitor |
|---|---|
| Also known as | Ertugliflozin and Sitagliptin |
| Sponsor | LMC Diabetes & Endocrinology Ltd. |
| Drug class | SGLT2 inhibitor and DPP-4 inhibitor combination |
| Target | SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 inhibitors increase urinary glucose excretion by inhibiting sodium-glucose cotransporter 2 in the proximal tubule. DPP-4 inhibitors prolong the action of incretin hormones (GLP-1 and GIP) by blocking dipeptidyl peptidase-4, thereby enhancing insulin secretion and reducing glucagon in response to meals. Together, these mechanisms provide complementary glucose-lowering effects with different sites of action.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Nasopharyngitis
- Headache
- Hypoglycemia (when combined with insulin or sulfonylureas)
Key clinical trials
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGLT2 inhibitor and DPP-4 inhibitor CI brief — competitive landscape report
- SGLT2 inhibitor and DPP-4 inhibitor updates RSS · CI watch RSS
- LMC Diabetes & Endocrinology Ltd. portfolio CI
Frequently asked questions about SGLT2 inhibitor and DPP-4 inhibitor
What is SGLT2 inhibitor and DPP-4 inhibitor?
How does SGLT2 inhibitor and DPP-4 inhibitor work?
What is SGLT2 inhibitor and DPP-4 inhibitor used for?
Who makes SGLT2 inhibitor and DPP-4 inhibitor?
Is SGLT2 inhibitor and DPP-4 inhibitor also known as anything else?
What drug class is SGLT2 inhibitor and DPP-4 inhibitor in?
What development phase is SGLT2 inhibitor and DPP-4 inhibitor in?
What are the side effects of SGLT2 inhibitor and DPP-4 inhibitor?
What does SGLT2 inhibitor and DPP-4 inhibitor target?
Related
- Drug class: All SGLT2 inhibitor and DPP-4 inhibitor combination drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)
- Manufacturer: LMC Diabetes & Endocrinology Ltd. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Ertugliflozin and Sitagliptin
- Compare: SGLT2 inhibitor and DPP-4 inhibitor vs similar drugs
- Pricing: SGLT2 inhibitor and DPP-4 inhibitor cost, discount & access